Pharmaceutical products
Original notice title
Germany-Hamburg: Pharmaceutical products
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
Open-house procedure attracts many suppliers, potentially leading to low margins.
Lack of estimated value and specific volume commitments makes it difficult to assess opportunity.
No procurement documents available
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Beschaffer: Bundesministerium für Wirtschaft und Energie (BMWE), Beschafftungsdienstleister: Forschungszentrum Jülich GmbH, Projektträger Jülich (PtJ)
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 31, 2099
Overview
Moderate opportunityKey Facts
- Supplies contract
- Pharmaceutical discount contracts (Rabattverträge) under §130a Abs. 8 SGB V
- Open-house procedure covering various active substances, combinations, and dosage forms
Show full summary
Open-house procedure (Rabattverträge) by Techniker Krankenkasse (TK) for pharmaceutical discount contracts on various active substances. The procedure is ongoing with no fixed deadline, allowing continuous submission. Awarded to lowest price. No estimated value or lot structure provided.
Risks
Open-house procedure attracts many suppliers, potentially leading to low margins.
Lack of estimated value and specific volume commitments makes it difficult to assess opportunity.
No procurement documents available
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer)
- No negotiation on terms; standard conditions apply
- No exclusivity guaranteed
Requirements may be incomplete.
Buyer
Location
Karlsruhe, DEU
Website
Activity
Defence
Procurement Details
- Publication date
- 25 Aug 2022
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 463590-2022
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
Open-house procedure attracts many suppliers, potentially leading to low margins.
Lack of estimated value and specific volume commitments makes it difficult to assess opportunity.
No procurement documents available
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications